Latest News

Administration expands OUD medication access while defunding SAMHSA and restricting harm reduction.

European price controls demonstrate MFN policy risks: delayed access, treatment rationing, and pharmaceutical innovation collapse.

Gamification as innovative approach to HIV prevention education for youth.

Grindr's at-home STI testing kits address barriers to sexual health testing.

Innovative approaches to improve HIV care transitions for people exiting incarceration.

Unintended consequences of Inflation Reduction Act drug pricing provisions.

ADAP coverage gaps for long-acting injectable HIV treatments and equity implications.

Major HIV research breakthroughs from CROI 2024: long-acting treatments and prevention advances.

CANN outlines organizational growth and 2024 policy priorities including state-level advocacy.

European Commission approves lenacapavir, a novel six-month injectable for treatment-resistant HIV.

Innovative HIV medications available but inaccessible: payer barriers block Cabenuva and Apretude access.

Access Health Louisiana uses animated series and radio to educate communities on HIV, HCV, and public health.

FDA reclassifies HCV testing to reduce regulatory burden and enable new test makers to enter market.

Nobel laureate's HCV vaccine development targeting 2029 offers hope alongside access equity challenges.

Explores technology innovations in HIV care including mobile apps and drone pharmacy delivery.

Merck-Gilead partnership on long-acting injectables Islatravir and Lenacapavir for HIV treatment.

COVID-19 vaccine development spurs reflection on 35-year HIV vaccine search and mRNA technology advances.

FDA approves Cabenuva, first long-acting injectable HIV regimen offering monthly alternative to daily pills.